EMA Head On Transparency, Affordable Innovation, And What Patients Really Need
Executive Summary
EMA will reinforce its role as a global reference authority and help build regulatory capacity in less experienced countries, Guido Rasi says in outlining his five-year priorities for the agency. He hopes regulatory efficiencies might contribute to lower drug prices.
You may also be interested in...
European Notebook: EMA’s 2016 Work Agenda; Clinical Trial Rule Delay; Ireland Benefits From Pfizer Merger
The European Medicines Agency wants to accelerate clinical development plans with new processes and procedures in 2016 and companies must disclose payments to providers starting mid-year; Ireland and Switzerland look set to grapple with high drug prices, and France's industry wants to reverse the erosion of jobs.
European Notebook: EMA’s 2016 Work Agenda; Clinical Trial Rule Delay; Ireland Benefits From Pfizer Merger
The European Medicines Agency wants to accelerate clinical development plans with new processes and procedures in 2016 and companies must disclose payments to providers starting mid-year; Ireland and Switzerland look set to grapple with high drug prices, and France's industry wants to reverse the erosion of jobs.
Adaptive Licensing: Industry On Board, With Caveats
The EU's adaptive licensing pilot project, which was launched in March 2014, is designed to deliver an early centralized marketing license for promising innovative therapies for patients with serious or life-threatening conditions. However, while the benefits are clear, there are a number of challenges that will need to be addressed.